Application of [(aryloxy)(heteroaryl)]methyl piperidine derivative in preparation of depression treatment drugs

The invention discloses an application of a compound represented by formula, or pharmaceutically acceptable salts thereof in the preparation of depression treatment drugs. The compound of formula I has a triple inhibition effect on 5-HT, NE and DA reuptake, and has wider adaptation and smaller neurological toxic side effects than single action target antidepressants (such as fluoxetine) and dual-action target antidepressants (such as duloxetine) which are clinically used at present in anti-depression.